Navigation Links
X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
Date:4/4/2013

WALTHAM, Mass. and LIANYUNGANG, China, April 4, 2013 /PRNewswire/ -- X-BODY BIOSCIENCES announced today an exclusive alliance with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), in which Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for Age-related Macular Degeneration (AMD) in Greater China (including mainland China, Taiwan, Macao, and Hong Kong).

Under the terms of the collaboration, Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts, for the Greater China markets.  X-BODY retains all development and commercialization rights outside of Greater China.  Detailed financial terms were not disclosed, but terms of the alliance include an upfront payment; clinical, regulatory and commercialization milestones; and royalties on revenues from commercialized products.

"It is an important part of our corporate strategy to partner with biotechs around the world that could provide interesting molecules for us to develop and commercialize, and we are excited to take on board the first of hopefully many development programs from X-BODY," said Lianshan Zhang, Ph.D., President of Global R&D, Jiangsu Hengrui Medicine Co., Ltd.

"This collaboration with Hengrui, the clear leader in pharmaceutical development in China, is an important step on our path to validate the capabilities of our DNA Display drug discovery platform.  We are encouraged to see our platform yield antibodies that could have a meaningful impact on patients' lives, especially for a disease as life-altering as AMD," added Julius Knowles , CEO of X-BODY.

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with annual R&D investment of over US$ 100 million. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with dozens of new molecular entities in clinical trials and under preclinical development.  Hengrui's products and R&D span over multiple therapeutic areas, such as oncology-hematology, anesthesiology, cardiovascular and metabolic diseases, ophthalmology, and inflammation. For more information, please visit http://www.hrs.com.cn/ and http://www.shhrp.com/.

About X-BODY Biosciences

X-BODY creates therapeutic antibodies against the most challenging and high-value drug targets, and is primarily focused on integral membrane proteins, such as GPCRs, ion channels, and transporters.  X-BODY is collaborating with leading biotech and pharmaceutical companies to progress its platform and its compounds.  X-BODY also generates antibodies internally, and has programs focused in oncology, ophthalmology, and metabolic diseases.  X-BODY is headquartered in Waltham, MA. For more information, please visit www.x-bodysciences.com


'/>"/>
SOURCE X-BODY BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Argon Medical Devices Announces The Launch Of OptionELITE Retrievable Vena Cava Filter And The Acquisition of Angiotech Interventional Business
2. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
3. Akorn, Inc. Announces First Quarter 2013 Earnings Release And Conference Call Information
4. Dynamic Healthcare Services Announces David Erb as Director of Sales
5. Cynosure Announces Presentation of 16 Abstracts at 33rd ASLMS Annual Conference
6. Organovo Holdings, Inc. Announces Change of Fiscal Year
7. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
8. China Botanic Pharmaceutical Inc. Announces Receipt of Notice of Failure to Satisfy Continued Listing Letter
9. MD+DI Announces 46 Innovative Products as Finalists in 2013 Medical Design Excellence Awards
10. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the First Quarter Ended March 31, 2013
11. Research and Markets Announces the Release of Cellulose Ethers Market By Derivative & Application - Global Trends & Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):